Clinical Trial Update: A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control [Phase 3]

View source ↗

Summary

A Phase 3 follow-up safety study assessing participants who received RSVPreF3 maternal vaccination or controls, with results posted for pregnancies conceived af…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSVPreF3 maternal vaccination (RSVPreF3)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 3 | Status: COMPLETED | Results posted: 2026-03-17